Biomedical Catalyst grant · Biotech
Alchemab wins £1.7m Innovate UK grant for Huntington’s programme
Biomedical Catalyst funding supports preclinical antibody development with Medicines Discovery Catapult.
Alchemab Therapeutics announced a £1.7 million grant from Innovate UK’s Biomedical Catalyst competition on 16 December 2022. The company is working with Medicines Discovery Catapult to develop an antibody programme for Huntington’s disease.
The award supports preclinical work on safety, efficacy and manufacturability as the collaborators prepare for potential first-in-human studies. Alchemab identifies candidate antibodies by studying people whose immune responses appear to provide unusual resistance to disease. This is the collaboration’s second grant from Innovate UK.
Use of funds
Develop resilient-patient antibody programme for Huntington disease